Leukemia in a patient treated with growth hormone.
It is well known that growth hormone (GH) therapy is associated with increased risk of development of malignant tumors, especially leukemia. In the case presented, growth hormone treatment was initiated in a 25-year-old patient with hypopituitarism. After 4 months of therapy with thrice a week injections of rhGH, acute myelogenous leukemia developed. It was thought that no clearcut evidence existed to establish a relationship between the growth hormone treatment and development of acute leukemia.
Aktan
M
M
Division of Hematology, Istanbul Medical School, University of Istanbul, Capa, Turkey.
Tanakol
R
R
Nalçaci
M
M
Dinçol
G
G
D000328:Adult; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D011994:Recombinant Proteins; D013006:Growth Hormone